Skip to main content Accessibility help

Longitudinal changes in functional disability in Alzheimer's disease patients

  • H. Michael Arrighi (a1), Isabelle Gélinas (a2), Trent P. McLaughlin (a1), Jacqui Buchanan (a1) and Serge Gauthier (a3)...


Background: Functional impairment is a core symptom of Alzheimer's disease (AD) often measured by loss of ability to perform activities of daily living (ADL). The objective is to describe the progressive loss of specific ADL functional capabilities expressed by AD patients’ cognitive ability.

Methods: Data are from ELN-AIP-901, an observational study of cognitive progression in participants aged 50–85 with AD (n = 196), mild cognitive impairment (n = 70), or cognitively normal (n = 75). Participants were evaluated using the Mini-Mental Status Exam (MMSE) and the Disability Assessment for Dementia (DAD) every six months for ≤2 years. Hierarchical regression was used to estimate annual change in DAD and MMSE; first, by individuals’ rate of change using linear regression, then controlling for baseline diagnosis.

Results: Over a two-year period, in AD participants, a 1-point change in MMSE was associated with a 3-point change in DAD (2.79, 95% CI: 1.97–3.63); DAD items within the finance, medication, and outings subdomains were impacted earlier than other subdomains; a hierarchy of functional impairment was observed, with instrumental ADL generally impaired prior to basic ADL.

Conclusions: ADL are impacted in a progressive and hierarchical manner associated with cognitive decline, but substantial variability remains among individuals, as well as in the relative order of items affected.


Corresponding author

Correspondence should be addressed to: H. Michael Arrighi, PhD, Janssen Alzheimer Immunotherapy Research & Development, LLC, 700 Gateway Blvd., South San Francisco, CA 94080, USA. Phone: +650-794-2568; Fax: +650-794-2504. Email:


Hide All
Andersen, C. K., Wittrup-Jensen, K. U., Lulk, A., Andersen, K. and Kragh-Sørenson, P. (2004). Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health and Quality of Life Outcomes, 2, 5258.
de Rotrou, al. (2012). DAD-6: A6-item version of the disability assessment for dementia scale which may differentiate Alzheimer's disease and mild cognitive impairment from controls. Dementia and Geriatric Cognitive Disorders, 33, 210218.
Feldman, H. H. and Woodward, M. (2005). The staging and assessment of moderate to severe Alzheimer's disease. Neurology, 65 (Supplement 3), S10S17.
Feldman, al. (2001). The Disability Assessment for Dementia Scale: a 12-month study of functional ability in mild to moderate Alzheimer's disease. Alzheimer Disease and Associated Disorders, 15, 8995.
Feldman, H. H., van Baelen, B., Kavanagh, S. M. and Torfs, K. E. (2005). Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Disease and Associated Disorders, 19, 2936.
Galasko, D., Edland, S. D., Morris, J. C., Clark, C., Moh, R. and Koss, E. (1995). The Consortium to Establish a Registry for Alzheimer's Dsease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology, 45, 4511455.
Gauthier, S. and Ballard, C. (2009). Management of Dementia, 2nd edn. New York: Informa Healthcare, 164 pp.
Gauthier, S., Gélinas, I. and Gauthier, L. (1997). Functional disability in Alzheimer's disease. International Psychogeriatrics, 9 (Supplement 1), 163165.
Gélinas, I., Gauthier, L., McIntyre, M. C. and Gauthier, S. (1999). Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. American Journal of Occupational Therapy, 53, 471481.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939944.
McLaughlin, al. (2010). Assessment of potential measures in models of progression in Alzheimer disease. Neurology, 75, 12561262.
Petersen, R. al. (2010). Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology, 74, 201209.
Salloway, al. (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 73, 20612070.
SAS Institute Inc. (2008). SAS Software 9.2. SAS Institute, Cary, NC.
Suh, G-H., Ju, Y-S., Yeon, B. K. and Shah, A. (2004). A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. International Journal of Geriatric Psychiatry, 19, 817824.


Type Description Title
Supplementary materials

Arrighi Supplementary Material

 Word (33 KB)
33 KB

Longitudinal changes in functional disability in Alzheimer's disease patients

  • H. Michael Arrighi (a1), Isabelle Gélinas (a2), Trent P. McLaughlin (a1), Jacqui Buchanan (a1) and Serge Gauthier (a3)...


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed